Imaging-Based Ultra-High Content Phenotyping

By Daniel Schaefer, Stefan Tomiuk, Laura N. Küster, Wa’el Al Rawashdeh, Janina Henze, German Tischler-Höhle, David J. Agorku, Janina Brauner, Cathrin Linnartz, Dominik Lock, Andrew Kaiser, Christoph Herbel, Dominik Eckardt, Melina Lamorte, Dorothee Lenhard, Julia Schüler, Philipp Ströbel, Jeannine Missbach-Guentner, Diana Pinkert-Leetsch, Frauke Alves, Andreas Bosio, and Olaf Hardt

Review this analysis into the discovery of targets for chimeric antigen receptor (CAR) T cell–based immunotherapy for pancreatic cancer. In this study, the MACSima Imaging Platform was applied to validate the tumor specificity of previously screened targets* as well as to better understand the biology behind the therapeutic responses in pre-clinical models.

Imaging-based high-content phenotyping is a powerful tool that can be applied to several steps of the drug discovery pipeline, however, current technologies can only provide information for a few selected proteins with limited spatial and single-cell resolution. Miltenyi Biotec's MACSima™ Imaging Platform addresses those limits by enabling fully automated, imaging-based ultra-high content phenotyping of hundreds of proteins, providing detailed information about their localization, quantification, and interactions down to single-cell level on several types of samples.